Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Animals (Basel) ; 14(13)2024 Jun 27.
Article in English | MEDLINE | ID: mdl-38998001

ABSTRACT

Diseases are responsible for losses in livestock production by increasing animal mortality and reducing productivity. The administration of antibiotics can help mitigate these negative effects. However, inappropriate use can lead to severe complications, such as raising antibiotic resistance. The purpose of this study was to perform a comparative analysis of antibiotic use and disease frequency over four years, based on the size of dairy farms and the type of farm. The study covered a 4-year period and included medium dairy farms (20-50 cows, n = 13), large dairy farms (>250 cows, n = 8), and large beef farms (n = 8). The collected data involved antimicrobial use but also included farm demographics, animal health, disease frequency, and herd management practices. The criteria used to categorise antibiotics into groups A-D were based on the EMA guidelines. The carried-out study showed that the large dairy cattle farms had the highest antibiotic consumption (18.29 mg·PCU-1), due to the high frequency of diseases, and consequently, the treatment of calf (diarrhoea, lung inflammations) and cow diseases (general treatment and mastitis). Cattle on large beef farms suffer mainly from general diseases caused by maintenance and herd management conditions. The use of restrict antibiotics was, in some cases, unjustified (antibiotics for dry cow therapy). Future studies should consider a larger number of farms, taking into account the given direction of cattle production.

2.
Phys Rev Lett ; 125(9): 091101, 2020 Aug 28.
Article in English | MEDLINE | ID: mdl-32915591

ABSTRACT

Many theories predict the existence of very heavy compact objects, that in terms of sizes would belong to the realms of nuclear or atomic physics, but in terms of masses could extend to the macroscopic world, reaching kilograms, tonnes, or more. If they exist, it is likely that they reach our planet with high speeds and cross the atmosphere. Because of their high mass-to-size ratio and huge energy, in many cases, they would leave behind a trail in the form of sound and seismic waves, etches, or light in transparent media. Here we show results of a search for such objects in visual photographs of the sky taken by the "Pi of the Sky" experiment, illustrated with the most stringent limits on the isotropic flux of incoming so-called nuclearites, spanning between 5.4×10^{-20} and 2.2×10^{-21} cm^{-2} s^{-1} sr^{-1} for masses between 100 g and 100 kg. In addition we establish a directional flux limit under an assumption of a static "sea" of nuclearites in the Galaxy, which spans between 1.5×10^{-18} and 2.1×10^{-19} cm^{-2} s^{-1} in the same mass range. The general nature of the limits presented should allow one to constrain many specific models predicting the existence of heavy compact objects and both particle physics and astrophysical processes leading to their creation, and their sources.

3.
Crit Rev Oncol Hematol ; 135: 47-58, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30819446

ABSTRACT

The checkpoint inhibitors have been continuously present in haematology for 20 years. From the first description, several of them were enrolled to the list of the oncological drugs. The research on nivolumab, avelumab, durvolumab is still in progress. In the treatment of some diseases, for instance, Hodgkin lymphoma, the programmed death cell pathway has already an important role. During the last years, the guidelines were enriched by using these drugs, both in solid and haematological malignancies. In this review, we present a history of discovery, research and clinical use of this new class of drugs potentially providing a significant change in curability rates of some haematological malignancies.


Subject(s)
Antineoplastic Agents/therapeutic use , B7-H1 Antigen/antagonists & inhibitors , Hematologic Neoplasms/drug therapy , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Drug Discovery , Humans , Nivolumab/therapeutic use
4.
Curr Probl Cancer ; 42(2): 231-234, 2018.
Article in English | MEDLINE | ID: mdl-29241676

ABSTRACT

Multiple myeloma is a hematological malignancy, which sometimes creates difficulties in diagnosis, based on the presence of monoclonal protein in serum/urine and plasmocyte infiltration in the bone marrow, and on the other hand, synchronous cancers are also a diagnostic challenge. We present a case report of a patient with concurrent breast cancer and multiple myeloma. A 68-year-old woman was admitted to the hospital with diagnosis of left breast cancer in first stage of the disease. In the past, she had had several episodes of thrombocytopenia, leucocytosis, and mild anaemia, which were followed by hematologist in outpatient setting. She was operated and started adjuvant chemotherapy. During treatment, episodes of hematological abnormalities were observed. After completion of the chemotherapy for breast cancer, the patient was observed and short time after that multiple myeloma was diagnosed as a synchronous cancer. Patient was first treated for breast cancer, then subsequently for multiple myeloma (2 lines therapy: CTD and VMP). We describe diagnostic problems with multiple myeloma; however, they could be caused by curation of breast cancer, which might have supressed the proliferation of plasmocytes and could delay the diagnosis. All symptoms of multiple myeloma were interpreted as a secondary effect of chemotherapy. Review of the literature shows the clinical approaches in such situations.


Subject(s)
Breast Neoplasms/diagnosis , Multiple Myeloma/diagnosis , Neoplasms, Multiple Primary/diagnosis , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/complications , Breast Neoplasms/therapy , Diagnosis, Differential , Female , Humans , Multiple Myeloma/complications , Multiple Myeloma/therapy , Neoplasms, Multiple Primary/therapy , Neoplasms, Second Primary/chemically induced , Neoplasms, Second Primary/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL